Survival Outcome and Optimal Candidates of Primary Tumor Resection for Patients With Metastatic Medullary Thyroid Cancer
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgae214 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Chu-Qiao Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Carcinoma, Neuroendocrine, SEER Program. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission Foundation of Shanghai Municipality.
Abstract (Originalsprache)
Context
Medullary thyroid cancer (MTC) often exhibits aggressive growth with distant organ metastasis, leading to poor survival.
Objective
The question of whether primary tumor resection (PTR) is beneficial for patients with metastatic MTC remains a subject of debate. In this study, we evaluated the prognostic significance of organ-specific metastases and the number of metastatic organs in these patients, and we also conducted an analysis to determine the therapeutic value of PTR in managing this rare malignancy. Materials and Methods Patients initially diagnosed with metastatic MTC were identified within the Surveillance, Epidemiology, and End Results database. Univariable and multivariable Cox proportional hazards regression models were performed to identify survival predictors. Survival outcomes were calculated using the Kaplan-Meier method and compared using the log-rank tests.
Results
A total of 186 patients with metastatic MTC at initial diagnosis from 2010 to 2020 were included. Bone, lung, and liver were the most common metastatic organs. Patients with brain metastasis had significantly worse overall survival (P = .007) and cancer-specific survival (P = .0013). Among all patients, 105 (56.45%) underwent PTR, and this group showed reduced overall mortality and cancer-specific mortality (all P < .05). When analyzing different metastatic patterns, PTR significantly lowered the risk of overall mortality and cancer-specific mortality for patients with bone, lung, liver, or distant lymph node involvement (all P < .05). Additionally, among patients with 1 or 2 metastases, those undergoing surgical resection were significantly associated with favorable overall survival (P = .008) and cancer-specific survival (P = .0247).
Conclusion
PTR may confer therapeutic benefits for carefully selected individuals with metastatic MTCs. To integrate these insights into clinical decision-making settings, it is imperative to undertake multicenter prospective studies in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
ORCID-Profile: Xiao Shi, Yu Wang, Wen-Jun Wei
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission Foundation of Shanghai Municipality
Zitieren
APA
Liu, C. Q., Shen, C. K., Du, Y. X., Li, Z. M., Shi, X., Wang, Y., & Wei, W. J. (2024). Survival Outcome and Optimal Candidates of Primary Tumor Resection for Patients With Metastatic Medullary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae214
Vancouver
Liu CQ, Shen CK, Du YX, Li ZM, Shi X, Wang Y, et al. Survival Outcome and Optimal Candidates of Primary Tumor Resection for Patients With Metastatic Medullary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae214
BibTeX
@article{Liu2024,
author = {Liu, Chu-Qiao and Shen, Cen-Kai and Du, Yu-Xin and Li, Zi-Meng and Shi, Xiao and Wang, Yu and Wei, Wen-Jun},
title = {Survival Outcome and Optimal Candidates of Primary Tumor Resection for Patients With Metastatic Medullary Thyroid Cancer},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgae214}
}
EUVIMED